| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H20N2O4S2 |
| Molecular Weight | 464.557 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(C=C1)C#CC2=CC=C(S2)S(=O)(=O)N[C@H](CC3=CNC4=CC=CC=C34)C(O)=O
InChI
InChIKey=YWCLDDLVLSQGSZ-JOCHJYFZSA-N
InChI=1S/C24H20N2O4S2/c1-16-6-8-17(9-7-16)10-11-19-12-13-23(31-19)32(29,30)26-22(24(27)28)14-18-15-25-21-5-3-2-4-20(18)21/h2-9,12-13,15,22,25-26H,14H2,1H3,(H,27,28)/t22-/m1/s1
| Molecular Formula | C24H20N2O4S2 |
| Molecular Weight | 464.557 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
S 3304 is a potent, orally active, noncytotoxic inhibitor of matrix metalloproteinases, primarily MMP-2 and MMP-9 that was developed by Shionogi as an anticancer agent. This drug has prolongs survival in mice xenografts and was well tolerated in healthy volunteers. S 3304 had completed phase I clinical trials for patients with locally advanced non-small cell lung cancer and with advanced solid tumors, however, the company had discontinued the further development of S 3304.